Go Pro
NASDAQ:SLXN

Silexion Therapeutics 5/13/2025 Earnings Report

Silexion Therapeutics logo
$0.35 +0.00 (+0.11%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.36 +0.01 (+2.10%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silexion Therapeutics EPS Results

Actual EPS
-$39.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silexion Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silexion Therapeutics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silexion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

Silexion Therapeutics Earnings Headlines

Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply got in before the Macintosh launch. Tech analyst George Gilder says a similar setup is forming today, but instead of one company, he points to three that he calls the Trillion Dollar Triangle. Gilder argues these three companies represent connected pieces of one major shift rather than competitors racing for the same outcome.tc pixel
See More Silexion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email.

About Silexion Therapeutics

Silexion Therapeutics (NASDAQ:SLXN) LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

View Silexion Therapeutics Profile